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Channelrhodopsin-2 (ChR2), a directly light-gated cat-
ion channel from the green alga Chlamydomonas rein-
hardtii has been shown to be a directly light-switched
cation-selective ion channel, which employs 11-cis
retinal as its chromophore. This is the same chromo-
phore as the mammalian photoreceptor’s visual pig-
ment—rhodopsin. Previously, investigators demon-
strated that ChR2 can be used to optically control
neuronal firing by depolarizing the cell. In this issue
of Neuron, Bi et al. apply viral-mediated gene transfer
to deliver ChR2 to retinal ganglion cells (RGC) in a ro-
dent model of inherited blindness. In this way, the
authors have genetically engineered surviving retinal
neurons to take on the lost photoreceptive function.
The conversion of light-insensitive retinal interneu-
rons into photosensitive cells introduces an entirely
new direction for treatments of blinding retinal degen-
eration.
Inherited retinal degenerations that cause partial or total
blindness affect one in 3000 people worldwide. Patients
afflicted with Usher syndrome develop progressive
deafness in addition to vision loss from retinal degen-
eration. There are currently no effective treatments or
cures for these conditions.
Basic research on treatment approaches for retinal
degeneration has long been separated into two groups:
treatments to preserve the remaining photoreceptors in
patients with retinal degenerative disease and methods
to replace photoreceptors lost to retinal degeneration. If
one attends a conference of patients afflicted with reti-
nal disease (http://www.ffb.ca/vq_conference2005.php?
hc=2&sub=5), attendees often group themselves into
patients seeking ways to slow the loss of their diminish-
ing vision and patients who are legally blind or NLP (no
light perception), having lost their photoreceptors be-
cause of an inherited eye disease or trauma. Currently
there are no therapies for inherited blinding disease
that restore vision. In the last decade, the development
of therapies designed to prevent blindness in patients
with inherited retinal disease who retain some functional
photoreceptors has come a long way. In particular,
neuroprotection with neurotrophic factors (LaVail et al.,
1992) and virus-vector-based delivery of wild-type
genes for recessive null mutations (Acland et al., 2001)
have come the furthest—to the point of a Phase I/II clini-
cal trial (Hauswirth, 2005) (Jacobson, S., Protocol
#0410-677, http://www.webconferences.com/nihoba/
16_jun_2005.html) gaining approval in the US for AAV-
mediated gene replacement therapy for Leber’s congen-
ital amaurosis, a form of retinal degeneration.
Up until now, there has been no evidence for the capa-
bility of retina to regenerate photoreceptors lost to apo-
ptosis. The genetics of retinal degeneration are com-
plex, with over 50 genes and 150 mutations identified
to date (http://www.sph.uth.tmc.edu/retnet/). The greatmajority of these defects involve photoreceptor specific
genes, and it is the rod and cone photoreceptors that are
lost in most retinal degenerations. The extremely hetero-
geneous nature of inherited retinal diseases makes the
design of gene replacement therapies challenging.
Gene replacement vectors will have to be very mutation
specific, further stratifying the patients in what is already
an orphan disease population. Nonetheless, there has
been remarkable progress in designing effective, ratio-
nal treatments for animal models of both recessive and
dominant retinal degenerations. In addition to gene re-
placement, neuroprotection by the overexpression of
neurotrophins has shown efficacy in slowing the loss
of photoreceptors regardless of the mutation (McGee
Sanftner et al., 2001). For dominant diseases involving
photoreceptor-specific genes, there are studies with
siRNA or ribozymes to knockdown the mutant gene
product (Lewin et al., 1998). Obviously, all of the afore-
mentioned strategies must be applied before the photo-
receptors are lost to apoptosis because blindness re-
sulting from loss of the rods and cones cannot be
ameliorated by gene augmentation or pharmaceutical
means. It is estimated that there are 130 million photore-
ceptors in a young adult, converging though a network
of interneurons onto w1 million retinal ganglion cells
(RGCs). Fortunately, the great number of photorecep-
tors translates into a long therapeutic window for these
diseases—clinical measures suggest that patients can
lose substantial numbers of photoreceptors without sig-
nificant loss of vision, providing there is not catastrophic
loss in the central retina (macula) (as occurs in ARMD—
age-related macular degeneration). Histopathology
studies in donor retina suggest that the inner retinal cells
are preserved for many years after the photoreceptors
are lost (Flannery et al., 1989); however, recent studies
in rodents demonstrate that these interneurons are not
static—there is significant retinal remodeling of the neu-
rons after synaptic input from photoreceptors is lost
(Jones et al., 2003) along with reactive gliosis of Mu¨ller
cells, the primary retinal glial cell (Fisher et al., 2005).
For patients in advanced stages of retinal degenera-
tion, it has been assumed that these therapies are not
applicable, and the photoreceptor cells must be re-
placed. For these individuals, the therapeutic options
are more limited and cell based, including transplanta-
tion of isolated photoreceptors or intact sheets of retina
(Seiler et al., 2005) or methods to differentiate embryonic
stem cells into photoreceptors. These therapies are still
several years off because the methods to control stem
cell fate determination or synaptic connection from
transplanted fetal retinal sheets or isolated photorecep-
tors to the host retina are yet to be developed. A parallel
path to therapy for the blind or partially sighted has been
the creation of retinal prosthetic ‘‘chip’’ devices (La-
khanpal et al., 2003), which use a photosensitive video
camera and electrode array to replace the photorecep-
tor’s light-signaling function. These devices have two
primary designs: a subretinal implant designed to have
a photoreceptive function and directly electrically stim-
ulate the second order retinal interneurons—the bipolar
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2Figure 1. Photoisomerization of Retinal
Gates Ionic Currents through Channelrho-
dopsin-2
Channelrhodopsin-2 (Chop2) is a seven trans-
membrane domain cation selective channel
that becomes photoswitchable when bound
to the chromophore 11-cis or all-trans retinal.
The chromophore bound channel (desig-
nated ChR2) opens in response to 460 nm
light, allowing cation flow in and depolarizing
the cell. In response to darkness, the channel
closes allowing the cell to once again reach its
resting membrane potential. Bi et al. express
a truncated Chop2 fragment (Met1-Lys315)
fused to green fluorescent protein (GFP) ex-
ogenously in retinal ganglion cells of blind
mice.cells—or an alternative design that utilizes an electrode
array to stimulate RGCs from the inner face of the retina.
In this issue, the authors (Bi et al., 2006) break new
ground in the application of a genetically encoded
light-sensitive channel, which they introduced into
RGCs of an animal model of blinding photoreceptor
degeneration. The channelopsin-2 (Chop2) protein, orig-
inally discovered in green algae, utilizes the same light-
sensitive chromophore—11-cis retinal as the rod photo-
receptor photopigment rhodopsin. As a result, its action
spectrum is similar to the cells whose function it is de-
signed to replace. Unlike rhodopsin, which only binds
the 11-cis conformation, Chop2 binds either 11-cis or
all-trans retinal isomers, obviating the need for the all-
trans to 11-cis isomerization reaction supplied by the
vertebrate visual cycle. When the retinal chromophore
is bound to Chop2, a functional light-sensitive channel
is formed, designated ChR2 (Chop2 retinalidene). The
authors have capitalized upon advancements in the field
by using viral vectors to transfer genes to retinal photo-
receptor cells (Flannery et al., 1997). With this strategy,
the investigators have made a paradigm shift in the field
and opened the possibility of genetically modifying the
surviving retinal interneurons to function as a replace-
ment light-sensing receptor.
Experimentally, the authors begin by demonstrating
the chosen adeno-associated viral (AAV) vector con-
struct efficiently targets RGCs, effectively delivering
the Chop2-GFP cDNA and expressing protein at high
levels after intravitreal injection in both normal and dis-
eased retinas. The authors systematically demonstrate
that when endogenous retinal is bound to ChR2, it can
be photoswitched (Figure 1), that neural activity can be
evoked in retinas and at cortical levels. This is shown
by several techniques—initially by in vitro patch-clamp
recordings of individual dissociated RGCs, followed by
multielectrode array recordings of whole-mount retina
preparations representative of a large population of
RGCs. Finally, they perform in vivo cortical recordings
from live blind mice to demonstrate critical connectionsare functionally maintained to higher visual centers.
Their progressive in vitro and in vivo data convincingly
suggests ectopic expression of ChR2 could provide a
future therapeutic strategy for restoring light sensitivity
to a ‘‘blind’’ retina.
Future behavior testing will undoubtedly determine if
converting RGCs into light sensors is a viable strategy
for restoring functional vision. Although many believe
that a highly plastic brain will have the capacity to
‘‘learn’’ to decode this new information presented by
light-sensitive RGCs, substantial processing (Roska
and Werblin, 2001), which normally occurs in the retina
itself, will be bypassed by this strategy. Exciting re-
search of this nature inevitably spawns many more un-
answered questions: will the neural activity evoked at
V1 be understood as ‘‘vision’’ on a cortical level? How
will receptive fields be influenced by having ChR2 ex-
pression in the long RGC axons, and therefore poten-
tially local depolarizations, as well as the soma?
The field is admittedly in its infancy, and there are sub-
stantial technical challenges to overcome. RGCs are
coarsely divided into two ON and OFF subpopulations,
based on their polarization response to light. Bi et al.
have effectively created an exclusively ON retina by ex-
pression of depolarizing ChR2 in all classes of RGCs.
What will the visual consequences be of an all ON retina?
Future refinements in viral targeting at the cellular trans-
duction and transcription level may aid in delivering
Chop2 and other light-sensitive channels to the appro-
priate class of RGCs in an attempt to restore receptive
field properties to the retina. In addition, there is the
need to develop channels that serve the opposite func-
tion, that is hyperpolarize in response to illumination and
target these channels to the OFF RGC subpopulation.
There has been progress along these lines by engineer-
ing nonlight-sensitive hyperpolarizing ion channels to
become light triggered (Banghart et al., 2004). Finally,
the ‘‘phototransduction cascade’’ in photoreceptors
generates a tremendous signal amplification that is
clearly not present in this light-activated channel. As
affect the shape but not rate of formation of recycled
synaptic vesicles.
Calcium triggering of synaptic vesicle exocytosis is me-
diated by calcium binding to the synaptic vesicle mem-
brane protein, synaptotagmin (Koh and Bellen, 2003).
Following exocytosis, synaptic vesicles are retrieved
by an endocytic mechanism. Two interesting features
of the latter process are that (1) in order to maintain ves-
icle pools and plasma membrane morphology, the rate
of synaptic vesicle endocytosis must be regulated to
match the rate of exocytosis; and that (2) endocytic pro-
teins must associate with cytoplasmic domains of syn-
aptic vesicle proteins in the context of plasma mem-
brane, but not in the context of synaptic vesicles.
Thus, there are at least two conceptually different regu-
latory steps: one determines the rate of endocytosis and
the other the need for endocytosis of vesicle proteins.
Experiments by Poskanzer et al. (2006) indicate that syn-
aptotagmin participates in both of these regulatory
steps, by distinct molecular mechanisms.
Syt’s involvement in endocytosis has long been sus-
pected, based not only on its biochemical interactions
with several endocytic proteins, but also on phenotypes
of C. elegans mutants lacking synaptotagmin (Jorgen-
sen et al., 1995). However, strong, direct evidence for
Syt function in synaptic vesicle reformation comes
from recent, parallel studies of Syt 1 mutant synapses,
both at the Drosophila neuromuscular junction and in
cultured mouse cortical neurons (Nicholson-Tomishima
and Ryan, 2004; Poskanzer et al., 2003). These analyses
measured kinetics of synaptic vesicle reformation using
a pH-sensitive green fluorescent protein (pHluorin) tar-
geted to the luminal domain of synaptic vesicles (Mie-
senbock et al., 1998). Thus, the differential fluorescence
of pHluorin exposed to pH 7 after exocytosis compared
to pHw6 within synaptic vesicles reports on the fraction
of vesicles in mature synaptic vesicles. Both papers
used clever methods to separate and measure rates of
exocytosis and endocytosis that occur simultaneously
at nerve terminals. For example, Nicholson-Tomishima
and Ryan (2004) used bafilomycin to block reacidifica-
tion of synaptic vesicles after exocytosis and thus mea-
sure the rate of exocytosis under given experimental
conditions. Poskanzer et al. (2003) used conditional
temperature shifts of shits mutants or temporally con-
trolled photoinactivation of FlAsH-tagged synaptotag-
min to isolate and analyze the role for Syt I in synaptic
vesicle endocytosis. Strikingly, both Drosophila and
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3a result, the RGC’s are substantially less light sensitive
than the intact retina. These are solvable problems.
This publication is clearly a significant first step into
this new field of re-engineering retinal interneurons as
genetically modified ‘‘prosthetic’’ cells.
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Synaptotagmin and Calcium
Do More between Bilayers
Building on recent findings that synaptotagmin (Syt)
participates in synaptic vesicle endocytosis, Pos-
kanzer et al., in this issue of Neuron, show distinct
mechanisms by which Syt functions in this process.
Most significantly, they show (1) that calcium binding
to Syt determines the rate but not fidelity of vesicle re-
cycling and (2) that mutations in a different Syt domain
mouse studies concluded that Syt I was necessary for
normal endocytosis of synaptic vesicles.
Here, exploiting previous structure-function analyses
of Syt (Chapman, 2002), Poskanzer et al. analyze how
Syt variants, with defects in specific molecular interac-
tions, function in synaptic vesicle recycling. First, they
make the very interesting observation that mutations in
the Ca2+-coordinating aspartate residues of the C2B do-
main (Syt-D3,4N), but not C2A, inhibit synaptic vesicle
recycling. This observation implicates for the first time
the calcium-binding function of Syt in vesicle recycling.
Direct evidence that the effect of these C2B mutations
is through altered calcium binding is provided by an
additional experiment. Increased extracellular calcium
substantially enhances recycling rates of synapses
